Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia
Carissa M. Feliciano(University of Southern California), Kevin R. Kelly(Keck Hospital of USC), George Yaghmour(University of Tennessee Health Science Center), Justin M. Watts(Sylvester Comprehensive Cancer Center), Hetty E. Carraway(Cleveland Clinic), Jennifer S. Carew(University of Arizona), Kaijin Wu(University of Southern California), Claudia M. Espitia(The University of Texas System), Julian Olea(University of Southern California), Mikkael A. Sekeres(University of Miami), Steffan T. Nawrocki(University of Arizona), Eduardo B. Fernández(Universidad Autónoma de Coahuila), Keri Maher(Virginia Cancer Institute), Homa Dadrastoussi(University of Southern California), Denice Tsao-Wie(University of Southern California), Brandon Sookdeo(University of Southern California), Xuelian Chen(Jiangsu University), Sharad Khurana(University of Arizona), Bhumika J. Patel(Cleveland Clinic), Stan G. Louie(University of Southern California)
Cited by 0
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782